Literature DB >> 24916472

The role of HIF1α in renal cell carcinoma tumorigenesis.

Lorraine J Gudas1, Leiping Fu, Denise R Minton, Nigel P Mongan, David M Nanus.   

Abstract

UNLABELLED: The transcription factor HIF1α is implicated in the development of clear cell renal cell carcinoma (ccRCC). Although HIF1α was initially believed to be essential for ccRCC development, recent studies hypothesize an oncogenic role for HIF2α in ccRCC, but a tumor suppressor role for HIF1α, leading to uncertainty as to the precise roles of the different HIF transcription factors in this disease. Using evidence available from studies with human ccRCC cell lines, mouse xenografts, murine models of ccRCC, and human ccRCC specimens, we evaluate the roles of HIF1α and HIF2α in the pathogenesis of ccRCC. We present a convergence of clinical and mechanistic data supporting an important role for HIF1α in promoting tumorigenesis in a clinically important and large subset of ccRCC. This indicates that current understanding of the exact roles of HIF1α and HIF2α is incomplete and that further research is required to determine the diverse roles of HIF1α and HIF2α in ccRCC. KEY MESSAGES: The TRACK mouse ccRCC model with constitutively active HIF1α but not HIF2α expressed in proximal tubules develops RCC. HIF1α protein is expressed in the majority of human ccRCC specimens. Elevated HIF1α in ccRCC correlates with a worse prognosis. Many publications do not support a tumor suppressor role for HIF1α in ccRCC. HIF1α, but not HIF2α, is expressed in some types of cancer stem cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24916472      PMCID: PMC4119538          DOI: 10.1007/s00109-014-1180-z

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  101 in total

1.  Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Authors:  Luciana Schultz; Alcides Chaux; Roula Albadine; Jessica Hicks; Jenny J Kim; Angelo M De Marzo; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

2.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

3.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

4.  ARNT-deficient mice and placental differentiation.

Authors:  K R Kozak; B Abbott; O Hankinson
Journal:  Dev Biol       Date:  1997-11-15       Impact factor: 3.582

5.  Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.

Authors:  V H Haase; J N Glickman; M Socolovsky; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

6.  Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.

Authors:  Leiping Fu; Gang Wang; Maria M Shevchuk; David M Nanus; Lorraine J Gudas
Journal:  Cancer Res       Date:  2013-02-27       Impact factor: 12.701

7.  The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer.

Authors:  Hye Ok Kim; Yong Hwa Jo; Juhie Lee; Sang Sook Lee; Kyung-Sik Yoon
Journal:  Oncol Rep       Date:  2008-11       Impact factor: 3.906

8.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.

Authors:  John D Gordan; Priti Lal; Vijay R Dondeti; Richard Letrero; Krishna N Parekh; C Elisa Oquendo; Roger A Greenberg; Keith T Flaherty; W Kimryn Rathmell; Brian Keith; M Celeste Simon; Katherine L Nathanson
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

9.  Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma.

Authors:  Christudas Morais; Helen Healy; David W Johnson; Glenda Gobe
Journal:  Nephrol Dial Transplant       Date:  2009-12-27       Impact factor: 5.992

10.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Authors:  Michael Zimmer; Darrell Doucette; Naila Siddiqui; Othon Iliopoulos
Journal:  Mol Cancer Res       Date:  2004-02       Impact factor: 5.852

View more
  38 in total

1.  Mesoscale nanoparticles selectively target the renal proximal tubule epithelium.

Authors:  Ryan M Williams; Janki Shah; Brandon D Ng; Denise R Minton; Lorraine J Gudas; Christopher Y Park; Daniel A Heller
Journal:  Nano Lett       Date:  2015-03-26       Impact factor: 11.189

2.  Five-year relative survival in sleep apnea patients with a subsequent cancer diagnosis.

Authors:  Arthur Sillah; Faiza Faria; Nathaniel F Watson; David Gozal; Amanda I Phipps
Journal:  J Clin Sleep Med       Date:  2020-02-06       Impact factor: 4.062

3.  Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically.

Authors:  Antoni Vilaseca; Daniel P Nguyen; Emily A Vertosick; Renato B Corradi; Mireia Musquera; Meritxell Pérez; Nicola Fossati; Daniel D Sjoberg; Ramon Farré; Isaac Almendros; Josep M Montserrat; Nicole E Benfante; A Ari Hakimi; Anders J Skanderup; Paul Russo; Antonio Alcaraz; Karim A Touijer
Journal:  World J Urol       Date:  2016-04-23       Impact factor: 4.226

4.  IL-37 mediates the antitumor activity in renal cell carcinoma.

Authors:  Yazhuo Jiang; Yili Wang; Liang Liang; Yang Gao; Juan Chen; Yi Sun; Yongyi Cheng; Yonggang Xu
Journal:  Med Oncol       Date:  2015-10-13       Impact factor: 3.064

5.  Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma.

Authors:  Denise R Minton; Leiping Fu; Nigel P Mongan; Maria M Shevchuk; David M Nanus; Lorraine J Gudas
Journal:  Clin Cancer Res       Date:  2016-01-18       Impact factor: 12.531

Review 6.  The HIF and other quandaries in VHL disease.

Authors:  D Tarade; M Ohh
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

7.  RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA.

Authors:  Rui-Li Zhang; Jun-Ping Yang; Li-Xia Peng; Li-Sheng Zheng; Ping Xie; Meng-Yao Wang; Yun Cao; Zhi-Ling Zhang; Fang-Jian Zhou; Chao-Nan Qian; Yong-Xing Bao
Journal:  Cell Cycle       Date:  2016-10-21       Impact factor: 4.534

8.  Sleep apnea and subsequent cancer incidence.

Authors:  Arthur Sillah; Nathaniel F Watson; Stephen M Schwartz; David Gozal; Amanda I Phipps
Journal:  Cancer Causes Control       Date:  2018-08-17       Impact factor: 2.506

9.  Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.

Authors:  C-H Chen; L W R Fong; E Yu; R Wu; J F Trott; R H Weiss
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

10.  In vivo and in vitro characteristic of HIF-1α and relative genes in ischemic femoral head necrosis.

Authors:  Wanglin Zhang; Zhe Yuan; Xinhong Pei; Ruixue Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.